Celcuity’s (CELC) “Buy” Rating Reaffirmed at HC Wainwright

Posted by George Bondi on Aug 15th, 2026

HC Wainwright reissued their buy rating on shares of Celcuity (NASDAQ:CELC – Free Report) in a report published on Friday,Benzinga reports. The firm currently has a $155.00 target price on the stock.

A number of other equities analysts have also issued reports on CELC. Stifel Nicolaus lowered their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday. Needham & Company LLC decreased their price objective on Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a research report on Friday. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Craig Hallum reiterated a “buy” rating and issued a $178.00 target price on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Wells Fargo & Company dropped their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and an average target price of $153.64.

Read Our Latest Research Report on CELC

Celcuity Stock Up 6.2%

Shares of NASDAQ:CELC opened at $92.00 on Friday. Celcuity has a 1-year low of $44.42 and a 1-year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The stock has a market cap of $4.49 billion, a P/E ratio of -21.40 and a beta of 0.20. The firm has a fifty day moving average price of $93.88 and a 200 day moving average price of $108.45.

Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Sell-side analysts predict that Celcuity will post -3.76 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC acquired a new stake in Celcuity in the second quarter valued at about $754,000. Legal & General Group Plc acquired a new position in Celcuity during the 2nd quarter worth approximately $1,763,000. The Manufacturers Life Insurance Company acquired a new position in Celcuity during the 2nd quarter worth approximately $2,927,000. Brandywine Managers LLC purchased a new position in shares of Celcuity during the 2nd quarter worth approximately $693,000. Finally, Nan Fung Group Holdings Ltd purchased a new position in shares of Celcuity during the 2nd quarter worth approximately $2,960,746,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Celcuity Company Profile

(Get Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.